Ocuphire and Opus Genetics merge to develop IRD gene therapy

Ocuphire Pharma acquires Opus Genetics to form Opus Genetics, focusing on gene therapy for inherited retinal diseases. The merger involves stock issuance and preferred shares conversion, aiming to accelerate the pipeline of gene therapies. The new company's president highlights the potential benefits for patients worldwide.